DKSH Holding has announced the acquisition of Swiss Refarmed Group, strengthening its capabilities in the life sciences. Through the acquisition, DKSH Business Unit Performance Materials, the leading global distributor of innovative pharmaceutical ingredients synthesis and formulation with vast and constantly growing global geographic reach, obtains a uniquely positioned business which provides value-added products and services for customers in the pharma industry across Europe, Asia Pacific, and the Americas. DKSH Switzerland will acquire the business and will fully integrate Refarmed Group into its existing operations.
Refarmed Group provides Active Pharmaceutical Ingredients and Finished Dosage Forms for generic drug manufacturers. This includes the sourcing of the ingredients as well as providing technical and regulatory support.
Headquartered in Switzerland, Refarmed’s team of pharmaceutical experts serves approximately 300 customers across Europe, Asia, and the Americas. Refarmed generates net sales of over CHF 60 million at sound profitability and return on capital.
Homburger has advised DKSH in this transaction. The team was comprised by partner Frank Gerhard (pictured), associates Anna Peter and Timo Hasler, junior associate Alexander Cochardt (all corporate / m&a), as well as partner Reto Heuberger and associate Laetitia Fracheboud (both tax).